These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 29900639)
21. Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering. Tribble JR; Hui F; Quintero H; El Hajji S; Bell K; Di Polo A; Williams PA Mol Aspects Med; 2023 Aug; 92():101193. PubMed ID: 37331129 [TBL] [Abstract][Full Text] [Related]
22. Should we treat the brain in glaucoma? Gupta N; Yücel YH Can J Ophthalmol; 2007 Jun; 42(3):409-13. PubMed ID: 17508036 [TBL] [Abstract][Full Text] [Related]
23. Assessment of neuroprotection in the retina with DARC. Guo L; Cordeiro MF Prog Brain Res; 2008; 173():437-50. PubMed ID: 18929126 [TBL] [Abstract][Full Text] [Related]
24. Protection of retinal ganglion cells in glaucoma: Current status and future. Shen J; Wang Y; Yao K Exp Eye Res; 2021 Apr; 205():108506. PubMed ID: 33609512 [TBL] [Abstract][Full Text] [Related]
25. [Possibilities of physiotherapy in glaucomatous optic neuropathy after glaucoma surgery]. Korzhavina AV; Sheludchenko VM; Yusef YN; Kosova JV; Volzhanin AV Vestn Oftalmol; 2024; 140(3):88-94. PubMed ID: 38962984 [TBL] [Abstract][Full Text] [Related]
27. Retinal ganglion cells and neuroprotection for glaucoma. Levin LA Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S21-4. PubMed ID: 12852431 [TBL] [Abstract][Full Text] [Related]
28. Addressing neurodegeneration in glaucoma: Mechanisms, challenges, and treatments. Bou Ghanem GO; Wareham LK; Calkins DJ Prog Retin Eye Res; 2024 May; 100():101261. PubMed ID: 38527623 [TBL] [Abstract][Full Text] [Related]
29. [Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part I]. Rokicki W; Dorecka M; Romaniuk W Klin Oczna; 2007; 109(7-9):349-52. PubMed ID: 18260296 [TBL] [Abstract][Full Text] [Related]
30. Current understanding of neuroprotection in glaucoma. Wein FB; Levin LA Curr Opin Ophthalmol; 2002 Apr; 13(2):61-7. PubMed ID: 11880717 [TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma. Shen C; Chen L; Jiang L; Lai TY Neurosci Lett; 2015 Jul; 600():132-6. PubMed ID: 26050640 [TBL] [Abstract][Full Text] [Related]
32. Current and emerging medical therapies in the treatment of glaucoma. Bagnis A; Papadia M; Scotto R; Traverso CE Expert Opin Emerg Drugs; 2011 Jun; 16(2):293-307. PubMed ID: 21406029 [TBL] [Abstract][Full Text] [Related]
33. Molecular and cell-based approaches for neuroprotection in glaucoma. Lebrun-Julien F; Di Polo A Optom Vis Sci; 2008 Jun; 85(6):417-24. PubMed ID: 18521011 [TBL] [Abstract][Full Text] [Related]
34. Neuroprotection by sodium channel blockade with phenytoin in an experimental model of glaucoma. Hains BC; Waxman SG Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4164-9. PubMed ID: 16249495 [TBL] [Abstract][Full Text] [Related]
35. History of neuroprotection and rationale as a therapy for glaucoma. Levin LA; Peeples P Am J Manag Care; 2008 Feb; 14(1 Suppl):S11-4. PubMed ID: 18284310 [TBL] [Abstract][Full Text] [Related]
36. Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury. Russo R; Adornetto A; Cavaliere F; Varano GP; Rusciano D; Morrone LA; Corasaniti MT; Bagetta G; Nucci C Mol Vis; 2015; 21():718-29. PubMed ID: 26167113 [TBL] [Abstract][Full Text] [Related]
37. Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine. Khatib TZ; Martin KR Curr Eye Res; 2020 Mar; 45(3):327-338. PubMed ID: 31475591 [No Abstract] [Full Text] [Related]
40. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Nucci C; Bari M; Spanò A; Corasaniti M; Bagetta G; Maccarrone M; Morrone LA Prog Brain Res; 2008; 173():451-64. PubMed ID: 18929127 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]